Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | HTR1B | P28222 | 2/20 | 0.30 |
| ▸ | HTR1D | P28221 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22983071 | 0.91 | MCHR1 (0.40) | HRH3MCHR1IDO1 | |
| SCHEMBL17648445 | 0.79 | NUDT1 (0.46) | — | |
| SCHEMBL4272939 | 0.79 | CYP2C9 (0.42) | MCHR1 | |
| SCHEMBL20261007 | 0.77 | — | — | |
| SCHEMBL1344981 | 0.77 | NR5A1 (0.40) | MCHR1 | |
| SCHEMBL3435460 | 0.76 | — | — | |
| SCHEMBL21452660 | 0.76 | — | — | |
| Phosphine SCHEMBL27351839 | 0.76 | NR5A1 (0.39) | MCHR1 | |
| SCHEMBL20239755 | 0.76 | MCHR1 (0.40) | MCHR1 | |
| SCHEMBL12633778 | 0.75 | TSHR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | HRH3 4131/4885MCHR1 4630/4885IDO1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.